[go: up one dir, main page]

NO20074360L - Behandling av metastaterte tumorer - Google Patents

Behandling av metastaterte tumorer

Info

Publication number
NO20074360L
NO20074360L NO20074360A NO20074360A NO20074360L NO 20074360 L NO20074360 L NO 20074360L NO 20074360 A NO20074360 A NO 20074360A NO 20074360 A NO20074360 A NO 20074360A NO 20074360 L NO20074360 L NO 20074360L
Authority
NO
Norway
Prior art keywords
treatment
compound
metastatic tumors
tautomer
pharmaceutically acceptable
Prior art date
Application number
NO20074360A
Other languages
English (en)
Inventor
Daniel Lopes De Menezes
Carla Heise
Xiaohua Xin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074360(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO20074360L publication Critical patent/NO20074360L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Fremgangsmåte for behandling av metastasert kreft slik som metastaserte tumorer inkludert å administrere en sammensetning av Struktur 1, en tautomer av sammensetningen, et farmasøytisk aksepterbart salt av sammensetningen, et farmasøytisk aksepterbart salt eller tautomeren, eller en blanding derav til et emne. Sammensetningen, tautomeren, saltet til sammensetningen, saltet til tautomeren eller blandinger derav kan bli benyttet for å fremstille medikamenter for behandling av metastasert kreft. Den variable A har verdiene definert heri.
NO20074360A 2005-01-27 2007-08-27 Behandling av metastaterte tumorer NO20074360L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US66924505P 2005-04-06 2005-04-06
US72205305P 2005-09-29 2005-09-29
PCT/US2006/002979 WO2006081445A2 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Publications (1)

Publication Number Publication Date
NO20074360L true NO20074360L (no) 2007-10-25

Family

ID=36741085

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074360A NO20074360L (no) 2005-01-27 2007-08-27 Behandling av metastaterte tumorer

Country Status (22)

Country Link
US (2) US20060183750A1 (no)
EP (2) EP2301546B1 (no)
JP (2) JP5371246B2 (no)
KR (1) KR101387985B1 (no)
CN (1) CN103893181A (no)
AT (1) ATE526025T1 (no)
AU (1) AU2006208012B2 (no)
BR (1) BRPI0607285A2 (no)
CA (1) CA2596084A1 (no)
CY (1) CY1112570T1 (no)
DK (1) DK1845990T3 (no)
ES (2) ES2374570T3 (no)
IL (1) IL184866A0 (no)
MA (1) MA29266B1 (no)
MX (1) MX2007009099A (no)
NO (1) NO20074360L (no)
PL (2) PL1845990T3 (no)
PT (2) PT1845990E (no)
SG (1) SG173317A1 (no)
SI (1) SI2301546T1 (no)
TN (1) TNSN07294A1 (no)
WO (1) WO2006081445A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US8299081B2 (en) * 2005-05-13 2012-10-30 Novartis Ag Methods for treating drug resistant cancer
EP1904480A2 (en) * 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
PL2558095T3 (pl) 2010-04-16 2019-06-28 Novartis Ag Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby
MX2013013437A (es) * 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
BR112014017985A8 (pt) * 2012-01-31 2017-07-11 Novartis Ag Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
CA2131528C (en) * 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) * 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
HUP0203323A3 (en) * 1999-10-19 2004-01-28 Merck & Co Inc Tyrosine kinase inhibitors and pharmaceutical compositions containing them
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
KR101167573B1 (ko) * 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
EP1885801A1 (en) * 2005-05-18 2008-02-13 M & G Polimeri Italia S.P.A. Polyester composition
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
PL1845990T3 (pl) 2012-02-29
KR101387985B1 (ko) 2014-04-25
MX2007009099A (es) 2007-09-13
WO2006081445A3 (en) 2007-01-11
ATE526025T1 (de) 2011-10-15
JP2008528617A (ja) 2008-07-31
CN103893181A (zh) 2014-07-02
WO2006081445A2 (en) 2006-08-03
DK1845990T3 (da) 2012-01-02
PT2301546E (pt) 2014-12-18
EP1845990A2 (en) 2007-10-24
SG173317A1 (en) 2011-08-29
PL2301546T3 (pl) 2015-03-31
CY1112570T1 (el) 2016-02-10
US20100173873A1 (en) 2010-07-08
KR20070118596A (ko) 2007-12-17
TNSN07294A1 (en) 2008-12-31
MA29266B1 (fr) 2008-02-01
EP2301546A1 (en) 2011-03-30
AU2006208012B2 (en) 2011-08-04
EP1845990B1 (en) 2011-09-28
EP1845990A4 (en) 2008-04-30
HK1155664A1 (en) 2012-05-25
JP2013177464A (ja) 2013-09-09
IL184866A0 (en) 2007-12-03
CA2596084A1 (en) 2006-08-03
SI2301546T1 (sl) 2015-01-30
BRPI0607285A2 (pt) 2009-08-25
ES2374570T3 (es) 2012-02-17
JP5371246B2 (ja) 2013-12-18
PT1845990E (pt) 2011-12-23
EP2301546B1 (en) 2014-09-10
AU2006208012A1 (en) 2006-08-03
US20060183750A1 (en) 2006-08-17
ES2525670T3 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
NO20074360L (no) Behandling av metastaterte tumorer
IL184951A0 (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
EA200700225A1 (ru) Аналоги тетрапептида
MX2009009574A (es) Tratamiento de melanoma.
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2006044826A3 (en) Thiophens and their use as anti-tumor agents
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
WO2008011113A3 (en) Thiadiazolidinone derivatives
WO2006044975A3 (en) Compositions and their use as anti-tumor agents
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
EP1364652A4 (en) DRUGS FOR LUNG CANCER
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
GB0305928D0 (en) Organic compounds
TW200706536A (en) Indole compounds
CY1113828T1 (el) Ενωσεις τριαζολιου που ρυθμιζουν δραστικοτητα hsp90

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application